西蒙顾和：2025中东欧国家医药市场定价与市场准入六大误区研究报告（英文版）（24页）.pdf

1、simon-Christian Schuler,Senior PartnerWiktor Miller,Senior ManagerSix P&MA myths about the pharmaceutical market in CEE countriesCommon misperceptions and realities-Comparing key P&MA success factors across 11 CEE markets with the EU-4ContentsIntroduction 3Six P&MA myths about the pharmaceutical mar

2、ket in CEE countries 4Myth 1:CEE markets offer only limited market potential 4Myth 2:CEE markets have a low willingness to adopt innovative pharmaceuticals 7Myth 3:CEE markets have highly complex P&MA processes with no transparent decision criteria 10Myth 4:CEE markets have significantly longer P&MA

3、 processes 12Myth 5:Low(list)price potential for innovative pharmaceuticals 14Myth 6:Risk of spillover to other EU markets 18Conclusions,recommendations,and strategic next steps 22Authors 233IntroductionCentral and Eastern Europes pharmaceutical landscape has evolved significantly in recent years.Ne

4、vertheless,outdated perceptions still influence how global pharmaceu-tical companies approach these markets,often leading to missed opportunities and suboptimal market access strategies.The region,home to 100 million people across all CEE markets(excluding Russia),holds significant untapped potentia

5、l,with many patients still lacking access to innovative medicines.Recent economic growth,constant healthcare system improvement and modernization,as well as evolving regulatory frameworks across CEE countries have created a highly dynamic market environment that differs substantially from historical

6、 misconceptions.This paper aims to challenge six prevalent myths about pharmaceutical markets in CEE countries,examining how they may impede effective market entry and expansion strategies.Using the major EU-4 markets(France,Germany,Italy,and Spain)as a reference point,we will analyze each myth agai